Skip to main content

Table 2 Comparison of OCS participants to non-participants from four recruiting sites

From: Representativeness of an HIV cohort of the sites from which it is recruiting: results from the Ontario HIV Treatment Network (OHTN) cohort study

Characteristics‡

Consented

Declined

Not approached

 
 

(n =1861)

(n =216)

(n =502)

p value

Site

    

  Windsor

128 (7%)

<6 (<3%)

94 (19%)

<.0001

  UHN

525 (28%)

162 (75%)

226 (45%)

 

  Ottawa

293 (16%)

35 (16%)

123 (25%)

 

  MLMC

915 (49%)

<16 (<7%)

59 (12%)

 

Age

46 (40–52)

45 (37–51)

44 (39–50)

0.008

Male

1632 (88%)

154 (71%)

374 (75%)

<.0001

Risk Factor

    

  MSM

1429 (77%)

90 (42%)

229 (47%)

<.0001

  IDU

180 (10%)

13 (6%)

49 (10%)

0.19

  Heterosexual

325 (18%)

93 (43%)

177 (36%)

<.0001

  Blood product

100 (5%)

10 (5%)

30 (7%)

0.46

Race

    

  Caucasian

1329 (72%)

76 (41%)

240 (57%)

<.0001

  Black/African

259 (14%)

75 (40%)

129 (31%)

 

  Other

259 (10%)

35 (19%)

49 (11%)

 

Born in Canada

1264 (69%)

78 (39%)

224 (52%)

<.0001

Years since HIV+ test

12 (5–18)

7 (5–14)

8 (4–13)

<.0001

On cART

1487 (80%)

156 (73%)

362 (73%)

0.001

CD4 count (cells/mm3)

480 (340–650)

450 (296–615)

420 (281–587)

<.0001

  <200

155 (8%)

31 (14%)

70 (15%)

<.0001

  200-500

851 (46%)

102 (47%)

227 (47%)

 

  >500

853 (46%)

82 (38%)

185 (38%)

 

VL <50 copies/mL

1379 (74%)

160 (75%)

297 (62%)

<.0001

  1. ‡ median (interquartile range) or frequency (percent).
  2. OCS Ontario HIV Treatment Network Cohort Study, UHN University Health Network, MLMC Maple Leaf Medical Clinic, MSM men who have sex with men, IDU injection drug use, cART combination antiretroviral therapy, VL viral load.